Sorting the trial evidence from the gray-market noise on an investigational triple agonist.
Retatrutide Legit

Citations

Sources: every citation used across this site.

DOIs and PubMed links for every reference. Primary literature where it exists; ClinicalTrials.gov for trial registrations.

Full citation list

The numbered references below correspond to in-text citations [1]-[14] across all pages on this site. Primary literature is linked to PubMed or PMC where available; trial registrations link to ClinicalTrials.gov.

  1. Jastreboff AM, et al. Triple-Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial. N Engl J Med. 2023;389(6):514-526. ↗
  2. Rosenstock J, et al. Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with type 2 diabetes: a randomised, double-blind, placebo and active-controlled, parallel-group, phase 2 trial. Lancet. 2023;402(10401):529-544. ↗
  3. Li W, Zhou Q, Cong Z, Yuan Q, Li W, Zhao F, Xu HE, Zhao LH, Yang D, Wang MW. Structural insights into the triple agonism at GLP-1R, GIPR and GCGR manifested by retatrutide. Cell Discovery. 2024;10:77. ↗
  4. Urva S, Coskun T, Loh MT, Du Y, Thomas MK, Gurbuz S, Haupt A, Benson CT, Hernandez-Illas M, D'Alessio DA, Milicevic Z. LY3437943, a novel triple GIP, GLP-1, and glucagon receptor agonist in people with type 2 diabetes: a phase 1b, multicentre, double-blind, placebo-controlled, randomised, multiple-ascending dose trial. Lancet. 2022;400:1869-1881. ↗
  5. Sanyal AJ, Kaplan LM, Frias JP, Brouwers B, Wu Q, Thomas MK, Harris C, Schloot NC, Du Y, Mather KJ, Haupt A, Hartman ML. Triple hormone receptor agonist retatrutide for metabolic dysfunction-associated steatotic liver disease: a randomized phase 2a trial. Nature Medicine. 2024;30:2037-2048. ↗
  6. Katsi V, Koutsopoulos G, Fragoulis C, Dimitriadis K, Tsioufis K. Retatrutide — A Game Changer in Obesity Pharmacotherapy. Biomolecules. 2025;15:796. ↗
  7. Caruso I, et al. Incretin-based therapies for the treatment of obesity-related diseases. npj Metabolic Health and Disease. 2024;2(1):31. ↗
  8. Eli Lilly and Company. The Effect of Retatrutide Once Weekly on Cardiovascular Outcomes and Kidney Function. ClinicalTrials.gov. 2024. ↗
  9. Eli Lilly and Company. A Study of Retatrutide (LY3437943) Compared to Tirzepatide (LY3298176). ClinicalTrials.gov. 2024. ↗
  10. Eli Lilly and Company. A Study of LY3437943 in Healthy Participants. ClinicalTrials.gov. 2019. ↗
  11. Gajos G, et al. Breaking the weight loss paradox: from weight reduction to cardiovascular benefit in obesity treatment. Polish Archives of Internal Medicine. 2025;135(3). ↗
  12. Savas M, et al. Beyond weight loss: multisystem benefits of obesity medications. The Lancet. Diabetes & Endocrinology. 2026. ↗
  13. et al. Retatrutide for the treatment of obesity, obstructive sleep apnea and knee osteoarthritis. Diabetes, Obesity and Metabolism. 2025. ↗
  14. Bailey CJ, et al. Multifunctional incretin peptides in therapies for type 2 diabetes, obesity and associated co-morbidities. Peptides. 2025. ↗
  15. Bhat S, et al. Efficacy and safety of incretin co-agonists: Transformative advances in cardiometabolic healthcare. World Journal of Cardiology. 2025;17(8):107991. ↗